Business

NMMC Government Hospital and Medical College, Vashi: Premier UG Medical Courses

Dec 11, 2024

PNN
Mumbai (Maharashtra) [India], December 11: NMMC Government Hospital and Medical College, Vashi, is a renowned institution offering quality medical education and healthcare services. Located in Navi Mumbai, it is equipped with modern facilities and experienced faculty, providing comprehensive training for future medical professionals.
The college offers four undergraduate (UG) programs:
1. MBBS (Bachelor of Medicine and Bachelor of Surgery): A premier course for aspiring doctors, emphasizing clinical and theoretical expertise.
2. BAMS (Bachelor of Ayurvedic Medicine and Surgery): Focuses on traditional Ayurvedic practices integrated with modern medicine.
3. BHMS (Bachelor of Homeopathic Medicine and Surgery): Specializes in homeopathy and holistic treatment methods.
4. BDS (Bachelor of Dental Surgery): Prepares students for a career in dentistry with in-depth knowledge of oral health sciences.
With robust academic and clinical training, the institution ensures students are well-prepared for successful medical careers.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025